Ann: Appendix 3G, Appendix 3H and Appendix 3Ys, page-20

First 20 Last

Share
Profile

Follow
whytee

16,588 Posts.

2364

08/07/23

00:46

Post #: 68682535
Share

Originally posted by sidat1984 ↑

As per the annual meeting notice the options, I guess this KPI has to be met before this options are exercised and not issued, correct?

For SI,

Vesting for the proposed issue of options will be contingent on achievement of the following milestones, being:
• LTI Commercialisation/Clinical KPIs – 60% (1,395,000 options): commercial and clinical milestones in relation
to the potential launch of remestemcel-L; and
• LTI Financial/Business KPIs – 40% (930,000 options): financial and business development milestones in relation
to remestemcel-L and rexlemestrocel-L platforms.

For Rose,

Vesting for the proposed issue of options will be contingent on achievement of the following milestones, being:
• LTI Regulatory KPIs (600,000 options): milestones related to the regulatory progress of remestemcel-L for
pediatric patients with SR-aGVHD with the United States Food and Drug Administration (FDA), including the
resubmission of its Biologics License Application and its potential approval by the FDA; and
• LTI Clinical KPIs (300,000 options): milestone related to the clinical progress of the Company’s lead products.

Expand

LoL,

met already.

"milestones in relation to the potential launch of remestemcel-L"

Not the commercial launch but a POTENTIAL launch... tick

"financial and business developmental milestones" cap raise, tick

"resubmission of the BLA" tick

"clinical progress" vague enough, I'm sure that must be a tick

MSB Price at posting: $1.13 Sentiment: Sell Disclosure: Not Held
4 Upvote

0 Great analysis

Reply